Divi’s Laboratories Q2 FY26 Concall Decoded: Peptides, Patience & a Pinch of Pricing Pressure
1. Opening Hook
When most pharma CEOs were busy explaining inventory “rationalization,” Dr. Kiran Divi was busy engineering a peptide revolution — one amino acid at a time. With contrast media bubbling, custom synthesis roaring, and generics sulking, Divi’s is now a curious mix of old-school chemistry and new-age biocatalysis. Yet, the company insists it’s not chasing glamour, just good science — and ₹689 crore of quarterly profit doesn’t hurt. Strap in, because between Kakinada, peptides, and patents, this call had more chemistry than your college lab.
2. At a Glance
Revenue up 17% – Chemistry clicked; spreadsheets sparkled.
EBITDA ₹912 Cr, up 26% – Lab coats turned into profit coats.
PAT ₹689 Cr, up 35% – Peptides paid the bills.
Exports 90% of revenue – India makes, world takes.
Custom Synthesis 56% mix – Outsourcing never sounded this profitable.
Capex ₹1,550 Cr (H1) – Still building, still billing.
Cash ₹3,451 Cr – Divi’s sits on a pharma-sized treasure chest.
3. Management’s Key Commentary
“We’ve delivered value across all business segments despite global trade dynamics.” (Translation: Even when China sneezes, our supply chain carries tissues. 😏)
“Unit 3 in Kakinada is now supporting in-house production of intermediates.” (Translation: We’re done begging vendors — DIY chemistry is the new mantra.)
“Peptide synthesis is gaining strong momentum; we’re working with big pharma.” (Translation: We’ve got friends in high molecular weight places.)
“Three major capex programs are underway with long-term commitments.” (Translation: Money’s going into reactors, not marketing brochures.)
“Exports to the U.S. and Europe form 74% of total.” (Translation: We sell wellness where healthcare costs more than cars.)
“Backward integration and flow chemistry will keep us future-ready.” (Translation: Divi’s doesn’t chase trends; it invents them.)
“We’ll continue to invest based on long-term sustainable contracts.” (Translation: Slow and steady, but with ₹2,000 crore capex flair. 🚀)
